Search | Clinical Trials Finder

Conditions: Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions: PANDA-VAC, Pembrolizumab; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alzheimer's Disease
Interventions: G-CSF; filgrastim, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 55 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Interventions: ReCharge, TakeCharge; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Keratolysis
Interventions: Riboflavin, Dextran, UVA Light Source; Drug · Device
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 10 more

Conditions: Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin; Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Septic Shock
Interventions: Vitamin C, Normal saline; Drug
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Bone Diseases, Infectious
Interventions: Debio 1450; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: La Mesa, California • Butte, Montana

Conditions: Healthy
Interventions: Salt Tablets, Electrolyte Solution; Dietary Supplement
Lead sponsor: National Aeronautics and Space Administration (NASA); Federal
Eligibility: 25 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: panitumumab, irinotecan hydrochloride, fluorouracil, leucovorin calcium; Biological · Drug
Lead sponsor: John Hays; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Columbus, Ohio • Nashville, Tennessee

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 43
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more

Conditions: Solid Tumours
Interventions: SB-715992, carboplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gastroenteritis, Dehydration
Interventions: 5% dextrose in normal saline; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 6 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: NIS793, Nab-paclitaxel, Gemcitabine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Dry Eye
Interventions: Secukinumab 10 mg/kg, Canakinumab 10 mg/kg, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes Mellitus
Interventions: Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee

Conditions: West Nile Virus
Interventions: Omr-lgG-am, Polygam® S/D, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Retinopathy of Prematurity (ROP)
Interventions: myo-Inositol 5% Injection, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Transient Hypothyroxinemia of Prematurity (THOP)
Interventions: thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Hour to 24 Hours
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes, Diabetes Distress
Interventions: StreamLine, TunedIn, FixIt; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 19 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Efficacy and Safety of Filgrastim in Alzheimer's Disease

Pilot of Pragmatic Delivery of Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

Dexamethasone/Pancreatic Clamp P&F

Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Fluid Loading Countermeasures

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

IVIG - West Nile Encephalitis: Safety and Efficacy

Inositol to Reduce Retinopathy of Prematurity

Study of Thyroid Hormones in Prematures

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control